Auna SA Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
1.4%projected annual EPS growth
Analyst Coverage
7analysts covering
FY Revenue (est.)
$1.4Bnext fiscal year
FY EPS (est.)
$0.25next fiscal year
Monitoring Framework
Key Performance Indicators
Consolidated Revenue Quarterly1.2BTarget: 12% FX-neutral growth for FY 2026 (range of 10% to 14%)
Consolidated Adjusted EBITDA Quarterly217MTarget: 12% FX-neutral growth for FY 2026 (range of 10% to 14%)
Leverage Ratio (Net Debt to Adjusted LTM EBITDA) Quarterly3.7xTarget: Below 3.0x in the medium term
Oncology Medical Loss Ratio (MLR) Quarterly4,960.0%Target: Sustained improvement and cost containment
Watch Items
- Foreign Exchange Volatility (USD/PEN)Trigger: Depreciation of the Peruvian Sol below the protective range of the call-spread hedging structureAction: Monitor non-cash FX losses on net finance costs and evaluate further adjustments to the hedging range
- Mexico Operations RecoveryTrigger: Lagging volume recoveries or margin compression at Doctors HospitalAction: Track sequential Adjusted EBITDA growth (19% QoQ in 1Q26) and the implementation of the new Hospital Information System and ERP
- Colombia Payor DiversificationTrigger: Revenues from government-intervened payors (e.g., Nueva EPS) exceeding 15% of total Colombia revenuesAction: Accelerate transition to risk-sharing agreements (PGPs) and expand relationships with non-intervened payors
Research as of 20 Jun 2026